Compare GSK plc (GSK) vs Ralph Lauren Corp (RL) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Ralph Lauren (RL) trades at $385.13, up 4.38% over the past day, with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from robust fundamentals including 69.87% gross margins and 34.66% ROE. Revenue growth accelerated to $7.08 billion in 2025, with net income reaching $743 million. Analyst sentiment remains positive with a $445.71 consensus price target, though technical indicators suggest near-term resistance at $386.

The outlook for RL is favorable given consistent earnings outperformance and brand strength in key markets like Asia. Risks include premium valuation multiples and macroeconomic pressures on consumer spending. Wall Street maintains a bullish stance with 66% of analysts rating it a Buy, projecting 16% upside from current levels based on continued digital and direct-to-consumer expansion.